Company profile

NImmune Biopharma

IBD-focused biotech (private)

Privately held: no public share price · USA

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
omilancorNo recent activity
Phase 3
LANCL2Small molecule
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease
NIM-1324
Preclinical
LANCL2Small molecule
Systemic Lupus Erythematosus

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.